Akebia Therapeutics, Inc. (AKBA) |
|
0.6388 -0.047 (-6.8%)
|
03-24 16:00 |
|
Open: |
0.69 |
Pre. Close: |
0.6854 |
|
High:
|
0.69 |
Low:
|
0.6135 |
|
Volume:
|
1,203,130 |
Market Cap:
|
118(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:23:54 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 1.05 One year: 1.26 |
| Support: |
Support1: 0.61 Support2: 0.5 |
| Resistance: |
Resistance1: 0.9 Resistance2: 1.08 |
| Pivot: |
0.75 |
| Moving Average: |
MA(5): 0.67  MA(20): 0.79
MA(100): 0.58 MA(250): 0.46 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 11 %D(3): 13.7 |
| RSI: |
RSI(14): 40.6 |
| 52-week: |
High: 1.2 Low: 0.24 |
| Average Vol(K): |
3-Month: 2,331 (K) 10-Days: 1,203 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ AKBA ] has closed above bottom band by 25.4%. Bollinger Bands are 60.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.69 - 0.69 |
0.69 - 0.7 |
|
Low:
|
0.61 - 0.61 |
0.61 - 0.61 |
|
Close:
|
0.63 - 0.64 |
0.64 - 0.64 |
|
Company Description |
|
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Fri, 24 Mar 2023
Akebia Therapeutics Files Revised Definitive Proxy Statement for ... - Victoria Advocate
Fri, 24 Mar 2023
Akebia Therapeutics Files Revised Definitive Proxy Statement for Special Stockholder Meeting - Yahoo Life
Fri, 17 Mar 2023
Akebia Therapeutics (NASDAQ:AKBA) Coverage Initiated by ... - MarketBeat
Thu, 16 Mar 2023
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Consensus ... - MarketBeat
Wed, 15 Mar 2023
Akebia Therapeutics Inc. (AKBA) Stock Faces 15.14% Weekly Volatility - The News Heater
Sun, 12 Mar 2023
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2022 Earnings Call Transcript - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
184 (M) |
| Shares Float |
167 (M) |
|
% Held by Insiders
|
1.2 (%) |
|
% Held by Institutions
|
29.2 (%) |
|
Shares Short
|
8,380 (K) |
|
Shares Short P.Month
|
3,320 (K) |
Stock Financials |
|
EPS
|
-0.47 |
|
EPS Est Next Qtl
|
-0.5 |
|
EPS Est This Year
|
-2.65 |
|
EPS Est Next Year
|
-1.73 |
|
Book Value (p.s.)
|
0.05 |
|
Profit Margin (%)
|
-31.7 |
|
Operating Margin (%)
|
-11.3 |
|
Return on Assets (ttm)
|
-4.7 |
|
Return on Equity (ttm)
|
-215.8 |
|
Qtrly Rev. Growth
|
-7.5 |
|
Gross Profit (p.s.)
|
0.76 |
|
Sales Per Share
|
1.58 |
|
EBITDA (p.s.)
|
0.02 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-73 (M) |
|
Levered Free Cash Flow
|
-13 (M) |
Stock Valuations |
|
PE Ratio
|
-1.36 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
12.77 |
|
Price to Sales
|
0.4 |
|
Price to Cash Flow
|
-1.61 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
